Cinclus Pharma: model update
Following last week’s licensing agreement with Zentiva for the EU rights to linaprazan glurate -valued at up to EUR220m - we have updated our model to reflect, i) the deal structure, including the total potential value and tiered double-digit royalties, and ii) a higher EU market penetration foreca
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.